Mortality from cirrhosis is primarily associated with decompensation of cirrhosis (development of ascites, hepatic encephalopathy, gastrointestinal bleeding, and progression to acute-on-chronic liver failure (ACLF). Despite multiple treatments, mortality of patients with decompensated cirrhosis remains high. The EU-funded DECISION project aims to understand the pathophysiology of cirrhosis decompensation leading to ACLF or death and to decrease patient mortality. The project will investigate the pathophysiology of cirrhosis decompensation by integrating the results of high-throughput multi-comic profiling with comprehensive clinical data from 2,200 fully characterized patients with available standardized biological samples. DECISION will help identify novel combinatorial therapies to prevent high mortality in patients with decompensating cirrhosis. Finally, researchers will optimize these therapies in new animal models and then test the best combination in high-risk patients in a phase II clinical trial.

Coordinator : EUROPEAN FOUNDATION FOR THE STUDY OF CHRONIC LIVER FAILURE (EF-CLIF)

Contact Joliot Institute: Christophe Junot (christophe.junot@cea.fr)

website

https://decision-for-liver.eu//

Agrément H2020 : 847949